Psilocybin-assisted psychotherapy for demoralization in advanced cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 interventional trial delivers a psilocybin-assisted psychotherapy protocol to adults aged 18–70 with stage 3 or 4 cancer and moderate-to-severe demoralization (Demoralization Scale ≥30). Participants will complete screening, psychotherapy preparation sessions, a supervised psilocybin administration session, and scheduled follow-up visits to monitor safety and symptom change. The primary focus is safety and tolerability, with collection of preliminary efficacy signals on demoralization, mood, and quality of life. All study procedures require in-person attendance at Queen's University in Kingston, Ontario.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients diagnosed with advanced stage cancer (stages 3 and 4)
* Aged between 18 and 70 years.
* Moderate-to-severe demoralization as measured by Demoralization Scale≥ 30
* English proficiency
* Ability to understand and the willingness to sign a written informed consent document.
* Individuals of child-bearing potential who are sexually active must agree to use an acceptable contraceptive method (hormonal or barrier method of birth control; abstinence) throughout their participation in the study. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled in this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of psilocybin administration.

Exclusion Criteria:

* Condition impairing oral intake or digestive absorption.
* Primary brain tumor.
* Presence of delirium.
* Significant suicide risk as defined by suicidal ideation with intent and a plan.
* Current or past history of schizophrenia, psychotic disorder, bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, or borderline personality disorder, as assessed by medical history.
* Patients with first-degree relatives with schizophrenia or bipolar disorder
* Previous diagnosis of epilepsy, stroke or Transient Ischemic Attack (TIA), dementia, and Parkinson's disease.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to psilocybin.
* Other personal circumstances and behavior that would limit compliance with study requirements or that are judged by the study psychiatrist and/or principal investigator to be incompatible with establishing rapport or safe exposure to psilocybin.
* Potential for adverse drug-drug interactions. Concomitant medications with significant potential to interact with study medications will be exclusionary if they cannot be tapered. These include the following:

  * MAO inhibitors
  * Patients currently on antipsychotics (e.g. first and second generation) when taken regularly (6 weeks or less prior to screening visit)
  * Mood stabilizers (e.g. lithium, valproic acid, lamotrigine)
  * Aldehyde dehydrogenase inhibitors (e.g. disulfiram)
  * Significant inhibitors of UGT 1A0 or UGT 1A10
* Patients who have elevated AST and ALT five times above the normal laboratory limit on their last available bloodwork performed at screening and patients with symptoms suggestive of liver failure including confusion, asterixis or jaundice.
* Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal condition or any other unstable condition that, in the opinion of the principal investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if he/she takes part in the study. This may include but is not limited to clinical symptoms or recent history of significant tachyarrhythmias; severe angina or myocardial ischemia; poorly controlled congestive heart failure; poorly controlled hypertension; poorly controlled hypo- or hyperthyroidism; uncontrolled diabetes; severe renal or liver dysfunction; acute respiratory failure; sepsis; history of cerebral aneurysms; glaucoma; increased intracranial pressure and any intracranial mass.
* Women who are pregnant, nursing, or planning a pregnancy.
* Use of a classic psychedelic or MDMA in the last 12 months

Where it's running

• Queen's University
  Kingston, Ontario, Canada Recruiting

Study contacts

• Study coordinator: Gustavo Vazquez, MD, PhD, FRCPC
• Email: vazquezg@providencecare.ca
• Phone: 613-544-4900 x51214

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using LSD to help relieve distress in terminally ill patients

  This study is testing if LSD can help reduce pain, anxiety, and depression in people who are terminally ill and improve their overall quality of life.

  Recruiting at 4 sites Phase 2 University Hospital, Basel, Switzerland · Basel and 3 other locations · NCT05883540

• Psilocybin therapy for demoralization in palliative care patients

  This study is testing if psilocybin therapy can help improve feelings of hopelessness in adults with serious illnesses who have a life expectancy of two years or less, compared to ketamine.

  Recruiting at 5 sites Phase 2 Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · Greenbrae, California and 4 other locations · NCT05403086

• SSS55 safety and how the body handles it in healthy adults

  This trial tests a single injection of SSS55 in healthy adults to see if it is safe, how the body processes it, and whether it triggers immune responses.

  Recruiting Phase 1 Shenyang Sunshine Pharmaceutical Co., LTD. · Shanghai, Shanghai Municipality · NCT07058779

• Be SMART secure firearm storage counseling for hospitalized caregivers

  This program will test whether a short Be SMART video and handout help caregivers of hospitalized children store firearms more safely at home.

  Recruiting at 2 sites Vanderbilt University Medical Center · Aurora, Colorado and 1 other locations · NCT06485141

• Registry for patients undergoing coronary intervention with orbital atherectomy

  This study is collecting information on patients with hard-to-treat heart blockages who are getting a specific procedure called orbital atherectomy to see how safe and effective it is.

  Recruiting at 2 sites Miedziowe Centrum Zdrowia SA · Legnica, Lower Silesian Voivodeship and 1 other locations · NCT06451146

• Evaluation of a new bone graft substitute for tooth extraction sites

  This study is testing a new bone graft substitute called Wishbone HA to see if it works as well as a standard option for helping people heal after tooth extractions.

  Recruiting at 5 sites Wishbone SA · Louvain-la-Neuve, Brabant Wallon and 4 other locations · NCT06383377

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.